Managed Access Programs for EXV811, Atrasentan
ConditionIgA Nephropathy
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorNovartis Pharmaceuticals
About this trial
The purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
An independent request was received from a licensed physician.
The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
Disqualifiers
None
Trial design
Treatments tested in this trial
Atrasentan
DrugPatients receive atrasentan
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov